A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (NCT00509769)
This was a multi-institutional, open-label, single-arm, Phase II study of ado-trastuzumab emtansine (T-DM1, Kadcyla®; Genentech, Inc.) administered by intravenous (IV) infusion to patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC).
This trial is sponsored by Genentech, Inc. 
- Condition: Metastatic Breast Cancer
- Phase: II
- Enrollment: 112
- Start: July 2007
- Completion: June 2009
- Last verified: February 2013
Last Editorial review: July 28, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.